Moreover, targeting MAPK signaling with trametinib, a MEK-ERK inhibitor clinically approved for BRAF-mutated melanoma32, reversed ERK phosphorylation and reduced mouse and human MM cell growth, which indicates shared MAPK activation (Fig. 3d,e). This evidence concerns the gene BRAF and Miyoshi myopathy.